Inactive Instrument

Highlights DENI THERPAR Nasdaq

Equities

Highlights

Unlock all the news: Be the first to know and act before the market!

Denali Therapeutics' Enzyme Replacement Therapy Picked for FDA's START Pilot Program; Shares Rise	06-03	MT
Denali Therapeutics Inc. Announces FDA Selects DNL126 for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies	06-03	CI
Denali Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating Eif2b Agonist Dnl343 in the Phase 2/3 Healey ALS Platform Trial	05-01	CI
Denali Therapeutics Files Prospectus for Secondary Offering	03-22	MT
Denali Shares Rise on PIPE Deal, Plan to Spin Out Preclinical Small Molecule Portfolio	02-27	MT
Denali Q4 Net Loss Widens; Launching PIPE Deal, Plans to Spin Out Preclinical Small Molecule Portfolio; Shares Jump Pre-Bell	02-27	MT
Denali Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-27	CI
North American Morning Briefing : S&P 500 Futures -2-	02-23	DJ
Denali Therapeutics Shares Fall After ALS Treatment Misses Primary Endpoint	02-16	DJ
Sanofi: failure of a phase 2 trial against ALS	02-16	CF
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier-Crossing Enzyme Replacement Therapy Programs At Worldsymposium	02-07	CI
Denali Therapeutics Inc. Announces Presentations on Its Investigational Blood-Brain Barrier-Crossing Enzyme Replacement Therapies At the Upcoming 2024 Worldsymposium	02-01	CI
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases	01-08	CI
Earnings Flash (DNLI) DENALI THERAPEUTICS Reports Q3 Revenue $1.3M	11-07	MT
Denali Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Denali Therapeutics Inc. Announces New Interim Data from Phase 1/2 Study of DNL310 in MPS II (Hunter Syndrome) at SSIEM 2023	23-08-30	CI
Earnings Flash (DNLI) DENALI THERAPEUTICS Reports Q2 Revenue $294.1M	23-08-08	MT
Denali Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Denali Therapeutics Announces Robust Reduction in Neurofilament Light with DNL310 Treatment in MPS II (Hunter Syndrome)	23-06-20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights DENI THERPAR Nasdaq

Equities

Highlights

Filters